I recently came across an article discussing a person with the diagnosis of Cochlear Otosclerosis? Exactly what does the diagnosis of Cochlear Otosclerosis entail? I am assuming a person must have Otosclerosis of the middle ear first in order to get Cochlear otosclerosis? Also I realize it causes SNHL, but what sort of damage does it do to the Inner ear? Some sources mention it causes permanent SNHL but that some medications may be prescribed to prevent further damage. From the House Ear Institute website, it states "in selected cases medication may be prescribed in an attempt to prevent further nerve impairment." What kind of medications are prescribed?
Yes you are correct, a person must have Otosclerosis of the middle ear first. Cochlear otosclerosis usually occurs in long standing case of otosclerotic fixation of the stapes where the disease process invades the otic capsule. This will begin and usually is contained in the basal turn of the cochlea. The otosclerosis process usually causes a conductive loss. As the disease invades the otic capsule a concomitant sensorineural loss will appear. Radiographic studies (High resolution CT scan) may sometimes reveal the otosclerotic lesion. In the demineralizing or spongiotic stage, normally sharp outline of the capsule becomes interrupted and can disappear. There are reports of otosclerotic invasion of the semicircular canals where dizziness may be a symptom as well.
Treatment for cochlear otosclerosis can include a sodium fluoride regimen. This is used as an attempt to retard or prevent further sensorineural hearing loss. This treatment is not considered a cure but a management technique. George Cire is the Clinical Manager for Bone Anchored Solutions at Cochlear Americas in Englewood, CO. Dr. Cire received his Au.D from A. T . Still University, School of Health Sciences in Mesa, AZ. Dr. Cire has been working in the Audiology field for 29 years.
George Cire, AuD
Clinical Manager, Bone Anchored Solutions, Cochlear Americas
George Cire currently works as Clinical Manager of Bone Anchored Solutions for Cochlear Americas in Englewood, Colorado. Prior to joining Cochlear, Dr. Cire has worked as a field specialist for Phonak Hearing Systems and has been a practicing Audiologist for 30 years. He has worked both in stand-alone private practice and as the director of an ENT affiliated Audiology Practice. His specialty interests are in the areas of clinical verification of amplification and vestibular diagnostics and treatment. Dr. Cire received his BA degree from Louisiana Tech University in Ruston, LA, M.C.D. (Master of Communicative Disorders) from Louisiana State University Health Sciences Center, New Orleans, LA and Au.D. from A. T. Still University, Arizona School of Health Sciences in Mesa, AZ.
This online course is designed to introduce those familiar with the Baha System in special considerations to the evaluation and selection of the appropriate sound processor to insure proper outcomes when fitting patients with SSD or Single Sided Deafness. Topics to be discussed will include: sound processor portfolio, sound processor adjustment and the introduction of consideration of the role of transcranial attenuation and it role in choosing the appropriate sound processor for SSD patients.
**FOR A GENERAL CERTIFICATE OF PARTICIPATION (No CEUs) PLEASE DOWNLOAD THE "COCHLEAR CERTIFICATE HANDOUT" AFTER REGISTRATION**
The goal of this course is to introduce the attendee to the advanced science of clinical pharmacology that impacts the practice of the audiologist. The clinical use and understanding of the pharmacodynamics, pharmacokinetics, and the potential positive and negative outcomes of medications will be emphasized.
It has been estimated that up to 60% of hearing loss is genetic. In this presentation, we will discuss the most common forms of genetic deafness, appropriate referrals to genetics professionals and what patients can expect from a genetics evaluation.
This article discusses issues surrounding hearing preservation with cochlear implantation surgery. This discussion includes factors that may affect hearing preservation with traditional cochlear implant devices as well as a discussion of research findings with hybrid/EAS devices. Editor's note 10/7/11: There have been rapid changes in the field of cochlear implantation thanks to ongoing advances in research and technology. Just since this article has been published, there are some very recent developments in EAS research at the University of Iowa. In the last three months, they have been given FDA approval to conduct two feasibility trials to study preservation of hearing with Nucleus hybrid cochlear implants in those with severe hearing loss and will be implanting children between the ages of 5 and 15 years of age. This new information about the Iowa-sponsored feasibility trials contradicts two points within questions 15 to 18 of the article: Adults with greater hearing impairment than those in the clinical trial described in the article are eligible for implantation with a Nucleus Hybrid L24 implant through the Iowa-sponsored feasibility trial, and the S12 and L24 devices are available to children through the feasibility study at the University of Iowa. Please keep this is mind as you read the article. As new advances are made in this exciting area of research and practice, we will try our best to keep you informed!